Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
News|Articles|May 11, 2024
Similar Efficacy of Ceftaroline and Vancomycin in Treating Complicated Skin and Soft Tissue Infections
Author(s)Sophia Abene
A comparative study presented MAD-ID, The Antimicrobial Stewardship Meeting examining the effectiveness of ceftaroline and vancomycin in addressing this challenge.
Advertisement
Complicated skin and soft tissue infections (cSSTIs), especially those caused by resistant pathogens like MRSA, pose a significant challenge in clinical management. The study findings suggest that ceftaroline and vancomycin demonstrate similar clinical cure rates for cSSTIs, despite potential differences in disease severity. While vancomycin led to shorter median hospital stays (3.9 days vs. 9 days for ceftaroline), no significant differences were observed in 30-day readmission rates, recurrence, time to oral antibiotic switch, or nephrotoxicity between the two treatment groups.
Despite numerically higher disease severity scores in the ceftaroline group, clinical cure rates remained comparable, with 88.7% for ceftaroline and 90.6% for vancomycin. Analysis of baseline characteristics revealed similarities between the two treatment groups, including median ages, body mass indexes (BMI), Acute Physiology and Chronic Health Evaluation (APACHE) scores, and Sequential Organ Failure Assessment (SOFA) scores.
The study conducted an interim analysis involving 106 individuals. The cohort consisted of adults diagnosed with cSSTIs who received at least 48 hours of either ceftaroline or vancomycin treatment and were discharged alive. Patients requiring prolonged antibiotic courses, combination therapy, pregnancy, or those incarcerated were excluded from the analysis.
In conclusion, further investigation into the full sample is warranted to comprehensively assess the efficacy and safety of both treatment modalities in managing cSSTIs caused by resistant pathogens like MRSA. This study holds promise for clinicians seeking optimized therapeutic strategies for challenging cSSTI cases.
Reference
Althubyani A, Beriashvili E, Wolowich W, et. al. Ceftaroline versus Vancomycin for the Treatment of Complicated Skin and Soft Tissue Infections (cSSTIs): A Retrospective Cohort Study. Abstract #53 OR presented MAD-ID The Antimicrobial Stewardship Meeting. May 8-11 Orlando, Florida.
Advertisement
Related to this article
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Labcorp data presented at IDWeek 2026 show measles PCR testing nearly quadrupled and positivity rose sharply from April 2025 through March 2026, as clinicians shift toward guideline-recommended molecular testing amid ongoing US outbreaks.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Advertisement
Advertisement